Physician profile
Arfa Faiz
NPI 1114314648
$2,466.30
in general payments reported to CMS, 2019-2025
16 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $248 · 2021: $350 · 2022: $250 · 2023: $49.82 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772 · Consulting Fee: $19.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.44 |
| Consulting Fee | $19.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $880.92 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $286.99 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $282.41 | 2019-2025 | Airsupra, Tezspire |
| Alk-Abello, INC | $257.17 | 2020-2023 | Odactra |
| Abbvie INC. | $124.99 | 2022 | |
| Melinta Therapeutics, LLC | $124.58 | 2022 | |
| Blueprint Medicines Corporation | $106.99 | 2025 | Ayvakit |
| Lilly USA, LLC | $95.22 | 2025 | Ebglyss |
| Takeda Pharmaceuticals U.S.A., INC. | $86.36 | 2020-2021 | |
| Glaxosmithkline, LLC. | $79.04 | 2021-2025 | Arexvy, Shingrix, Nucala |
| Ionis Pharmaceuticals, INC. | $41.13 | 2025 | Dawnzera |
| Csl Behring | $27.42 | 2025 | Haegarda |
| Phadia US INC. | $24.71 | 2021 | |
| Adma Biomanufacturing LLC | $19.26 | 2025 | |
| Pharming Healthcare, INC. | $14.82 | 2025 | Ruconest |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arfa Faiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.